Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI 369815
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
MEDI 369815 is a monovalent, live-attenuated influenza virus (LAIV) strain developed for use in clinical research, specifically within controlled human infection models (CHIM). It is based on the A/Norway/31694/2022 (H1N1)pdm09-like strain, which corresponds to the World Health Organization's (WHO) recommendations for the H1N1 component of influenza vaccines for the 2023–2024 Northern Hemisphere season. The virus is engineered using a cold-adapted, temperature-sensitive, and attenuated master donor virus backbone, which restricts its replication to the cooler environment of the upper respiratory tract. Developed by AstraZeneca (MedImmune) and utilized in studies led by the Leiden University Medical Center (LUMC), MEDI 369815 is designed to safely induce a mild, self-limiting infection in healthy volunteers. This allows for the detailed study of viral kinetics, mucosal immunology, and the evaluation of the protective efficacy of candidate influenza vaccines and antiviral therapeutics in a controlled setting.
- Other names
- influenza virus A/Victoria/4897/2022 (H1N1)pdm09-like strainA/Norway/31694/2022A/Norway/31694/2022 (H1N1)pdm09-like strain
02
Targets
Sialoglycan (Cell-surface sialoglycan)α2,6-Sia (Alpha-2,6-linked sialic acid)
Beyond the preview
Go deeper on MEDI 369815.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI 369815.